IDH305

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, NYU Langone Health, University of Texas Southwestern Medical Center

Conditions

Acute Myeloid Leukemia (AML)Advanced Malignancies That Harbor IDHR132 MutationsGlioma

Phase 1

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Active, not recruitingNCT02381886

Novartis PharmaceuticalsAdvanced Malignancies That Harbor IDHR132 Mutations

Start: 2015-03-06End: 2030-10-31Updated: 2026-04-13

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

WithdrawnNCT02826642

Novartis PharmaceuticalsAcute Myeloid Leukemia (AML)

Start: 2016-08-26End: 2016-11-29Updated: 2019-04-10

Phase 2

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

WithdrawnNCT02977689

NYU Langone HealthGlioma

Start: 2018-04-30End: 2020-04-30Updated: 2017-12-20

Phase 2 Study of IDH305 in Low Grade Gliomas

WithdrawnNCT02987010

University of Texas Southwestern Medical CenterGlioma

Start: 2017-01-31End: 2019-01-31Updated: 2017-10-11

Related Papers

A phase 1 study of IDH305 in patients with IDH1<sup>R132</sup>-mutant acute myeloid leukemia or myelodysplastic syndrome.

2022-03-3020 citations

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions

HemaSphere2021-06-0112 citations

Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032

Cancers2020-10-2913 citations

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations

Blood2016-12-0259 citations